M&ACan Sanofi buy its way into in vivo CAR-T?Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from … more ➔
Start-upBionyra launches with $165m, France’s largest biotech Series AWith an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year … more ➔
licensingBioArctic signs potential $1bn Alzheimers research deal with Eli LillyBioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with … more ➔
investmentNovo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discoveryThe Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation … more ➔
licensingJazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCelleraDublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and … more ➔
clinical dataF2G’s oral antifungal clears Phase III hurdleUK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening … more ➔
RegulatoryFDA opens path for uniQure’s Huntington’s gene therapy filingAfter months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130. more ➔
NIHPsychiatryFunding: HMNC and the Long Road to Precision PsychiatryWith a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important … more ➔
FundraisingAplagon raises €4.8m to expand antithrombotic into new Phase II trialFinnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing … more ➔
Venture capitalKos Biotechnology raises US$123m for Greek life sciences fundKos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem. more ➔
NIH
